Mechanisms of Intradialytic Hypertension

Sympathetic Regulation in Intradialytic Hypertension

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01947673

Acronym

MID-H

Enrollment

Registered

2013-09-20

Start date

2013-09-30

Completion date

2017-11-30

Last updated

2021-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemodialysis-induced Symptom, Hypertension, Renal Failure Chronic Requiring Hemodialysis

Brief summary

Patients with end-stage renal disease (ESRD) are at significantly higher risk for death due to cardiovascular disease. Those with paradoxical increases in blood pressure (BP) during hemodialysis (HD), defined as intradialytic hypertension (IDH), are at even greater risk of cardiovascular mortality. This study seeks to determine the mechanisms that underlie IDH, and whether mindfulness meditation might improve BP during dialysis in these patients. The investigators will first determine if increased adrenaline levels during volume removal contributes to IDH. The investigators will then determine lack of suppression of adrenaline levels in the setting of a high BP also contributes to IDH. This will be done by manipulating blood pressure by using small amounts of vasoactive drugs, and determining if an appropriate response in adrenaline levels occurs. Lastly, the investigators will determine if an intradialytic mindfulness meditation program improves BP and adrenaline levels in ESRD patients with IDH.

Interventions

OTHERMindfulness Meditation

OTHERHealth Education

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* ESRD patients on maintenance hemodialysis for at least 6 months, with increased blood pressure during hemodialysis

Exclusion criteria

* drug or alcohol abuse * any serious systemic disease that might influence survival * severe anemia with hgb level \<8 g/dL * clinical evidence of congestive heart failure * ejection fraction below 35% * myocardial infarction or cerebrovascular accident within the past six months * symptomatic heart disease determined by electrocardiogram, stress test, and/or history * treatment with central alpha agonists or monoamine oxidase (MAO) inhibitors * peripheral neuropathy * autonomic dysfunction * pregnancy * surgery within the past 3 months

Design outcomes

Primary

Measure	Time frame
Blood Pressure during dialysis	8 weeks
Cardiopulmonary baroreflex Sensitivity	8 weeks

Secondary

Measure	Time frame
Kidney Disease Quality of Life (KDQOL) Symptom Score	8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026